NCT00598845

Molecular Markers in Treatment in Endometrial Cancer

Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens.

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: University of Bergen · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this prospective multicenter trial is to investigate the value of molecular markers in endometrial cancer for predicting lymph node metastasis and prognosis in relation to treatment.

Detailed description

This is a prospective multicenter study to investigate the predictive value of molecular markers in endometrial cancer for lymph node metastasis, prognosis and treatment. For the previously studied tumor markers p53, p16, ER, PR and HER2neu, we want to investigate the expression in curettage material in relation to lymph node metastasis and prognosis among endometrial carcinoma patients. We also want to investigate the distribution of genetic alterations in fresh frozen tumor tissue in order to design prospective randomized treatment trials of metastatic endometrial cancer based on molecular profile. There will be a special emphasis on disturbances in the pathways influenced by new targeted therapy, such as inhibitors of Her2/NEU, EGFR, receptor tyrosine kinase, mTOR, PTEN and hormone receptor pathways.

Conditions

• Endometrial Neoplasms
• Neoplasm Metastasis

Interventions

Type	Name	Description
PROCEDURE	Tumor biopsy study	Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.

Timeline

• Start date: 2001-04-01
• Primary completion: 2015-12-01
• Completion: 2017-12-01
• First posted: 2008-01-23
• Last updated: 2014-12-23

Locations

9 sites across 3 countries: Belgium, Norway, Sweden